An autophagy-inducing and TLR-2 activating BCG vaccine induces a robust protection against tuberculosis in mice

Arshad Khan, Pearl Bakhru, Sankaralingam Saikolappan, Kishore Das, Emily Soudani, Christopher R. Singh, Jaymie L. Estrella, Dekai Zhang, Chandrashekhar Pasare, Yue Ma, Jianjun Sun, Jin Wang, Robert L. Hunter, N. Tony Eissa, Subramanian Dhandayuthapani, Chinnaswamy Jagannath

Research output: Contribution to journalArticle

Abstract

Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis due to M. tuberculosis (Mtb), which kills millions of people each year. BCG variably protects children, but not adults against tuberculosis. BCG evades phagosome maturation, autophagy, and reduces MHC-II expression of antigen-presenting cells (APCs) affecting T-cell activation. To bypass these defects, an autophagy-inducing, TLR-2 activating C5 peptide from Mtb-derived CFP-10 protein was overexpressed in BCG in combination with Ag85B. Recombinant BCG85C5 induced a robust MHC-II-dependent antigen presentation to CD4 T cells in vitro, and elicited stronger TH1 cytokines (IL-12, IL-1β, and TNFα) from APCs of C57Bl/6 mice increasing phosphorylation of p38MAPK and ERK. BCG85C5 also enhanced MHC-II surface expression of MΦs by inhibiting MARCH1 ubiquitin ligase that degrades MHC-II. BCG85C5 infected APCs from MyD88 or TLR-2 knockout mice showed decreased antigen presentation. Furthermore, BCG85C5 induced LC3-dependent autophagy in macrophages increasing antigen presentation. Consistent with in vitro effects, BCG85C5 markedly expanded both effector and central memory T cells in C57Bl/6 mice protecting them against both primary aerosol infection with Mtb and reinfection, but was less effective among TLR-2 knockout mice. Thus, BCG85C5 induces stronger and longer lasting immunity, and is better than BCG against tuberculosis of mice.

Original languageEnglish (US)
Article number34
Journalnpj Vaccines
Volume4
Issue number1
DOIs
StatePublished - Dec 1 2019
Externally publishedYes

Fingerprint

BCG Vaccine
Autophagy
Mycobacterium bovis
Tuberculosis
Antigen Presentation
Antigen-Presenting Cells
T-Lymphocytes
Knockout Mice
Tuberculosis Vaccines
Phagosomes
Interleukin-12
Ligases
Ubiquitin
Aerosols
Interleukin-1
Immunity
Macrophages
Phosphorylation
Cytokines
Infection

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Khan, A., Bakhru, P., Saikolappan, S., Das, K., Soudani, E., Singh, C. R., ... Jagannath, C. (2019). An autophagy-inducing and TLR-2 activating BCG vaccine induces a robust protection against tuberculosis in mice. npj Vaccines, 4(1), [34]. https://doi.org/10.1038/s41541-019-0122-8

An autophagy-inducing and TLR-2 activating BCG vaccine induces a robust protection against tuberculosis in mice. / Khan, Arshad; Bakhru, Pearl; Saikolappan, Sankaralingam; Das, Kishore; Soudani, Emily; Singh, Christopher R.; Estrella, Jaymie L.; Zhang, Dekai; Pasare, Chandrashekhar; Ma, Yue; Sun, Jianjun; Wang, Jin; Hunter, Robert L.; Tony Eissa, N.; Dhandayuthapani, Subramanian; Jagannath, Chinnaswamy.

In: npj Vaccines, Vol. 4, No. 1, 34, 01.12.2019.

Research output: Contribution to journalArticle

Khan, A, Bakhru, P, Saikolappan, S, Das, K, Soudani, E, Singh, CR, Estrella, JL, Zhang, D, Pasare, C, Ma, Y, Sun, J, Wang, J, Hunter, RL, Tony Eissa, N, Dhandayuthapani, S & Jagannath, C 2019, 'An autophagy-inducing and TLR-2 activating BCG vaccine induces a robust protection against tuberculosis in mice', npj Vaccines, vol. 4, no. 1, 34. https://doi.org/10.1038/s41541-019-0122-8
Khan, Arshad ; Bakhru, Pearl ; Saikolappan, Sankaralingam ; Das, Kishore ; Soudani, Emily ; Singh, Christopher R. ; Estrella, Jaymie L. ; Zhang, Dekai ; Pasare, Chandrashekhar ; Ma, Yue ; Sun, Jianjun ; Wang, Jin ; Hunter, Robert L. ; Tony Eissa, N. ; Dhandayuthapani, Subramanian ; Jagannath, Chinnaswamy. / An autophagy-inducing and TLR-2 activating BCG vaccine induces a robust protection against tuberculosis in mice. In: npj Vaccines. 2019 ; Vol. 4, No. 1.
@article{0bea025b56944dfa99ca53c1a214a55c,
title = "An autophagy-inducing and TLR-2 activating BCG vaccine induces a robust protection against tuberculosis in mice",
abstract = "Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis due to M. tuberculosis (Mtb), which kills millions of people each year. BCG variably protects children, but not adults against tuberculosis. BCG evades phagosome maturation, autophagy, and reduces MHC-II expression of antigen-presenting cells (APCs) affecting T-cell activation. To bypass these defects, an autophagy-inducing, TLR-2 activating C5 peptide from Mtb-derived CFP-10 protein was overexpressed in BCG in combination with Ag85B. Recombinant BCG85C5 induced a robust MHC-II-dependent antigen presentation to CD4 T cells in vitro, and elicited stronger TH1 cytokines (IL-12, IL-1β, and TNFα) from APCs of C57Bl/6 mice increasing phosphorylation of p38MAPK and ERK. BCG85C5 also enhanced MHC-II surface expression of MΦs by inhibiting MARCH1 ubiquitin ligase that degrades MHC-II. BCG85C5 infected APCs from MyD88 or TLR-2 knockout mice showed decreased antigen presentation. Furthermore, BCG85C5 induced LC3-dependent autophagy in macrophages increasing antigen presentation. Consistent with in vitro effects, BCG85C5 markedly expanded both effector and central memory T cells in C57Bl/6 mice protecting them against both primary aerosol infection with Mtb and reinfection, but was less effective among TLR-2 knockout mice. Thus, BCG85C5 induces stronger and longer lasting immunity, and is better than BCG against tuberculosis of mice.",
author = "Arshad Khan and Pearl Bakhru and Sankaralingam Saikolappan and Kishore Das and Emily Soudani and Singh, {Christopher R.} and Estrella, {Jaymie L.} and Dekai Zhang and Chandrashekhar Pasare and Yue Ma and Jianjun Sun and Jin Wang and Hunter, {Robert L.} and {Tony Eissa}, N. and Subramanian Dhandayuthapani and Chinnaswamy Jagannath",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41541-019-0122-8",
language = "English (US)",
volume = "4",
journal = "npj Vaccines",
issn = "2059-0105",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - An autophagy-inducing and TLR-2 activating BCG vaccine induces a robust protection against tuberculosis in mice

AU - Khan, Arshad

AU - Bakhru, Pearl

AU - Saikolappan, Sankaralingam

AU - Das, Kishore

AU - Soudani, Emily

AU - Singh, Christopher R.

AU - Estrella, Jaymie L.

AU - Zhang, Dekai

AU - Pasare, Chandrashekhar

AU - Ma, Yue

AU - Sun, Jianjun

AU - Wang, Jin

AU - Hunter, Robert L.

AU - Tony Eissa, N.

AU - Dhandayuthapani, Subramanian

AU - Jagannath, Chinnaswamy

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis due to M. tuberculosis (Mtb), which kills millions of people each year. BCG variably protects children, but not adults against tuberculosis. BCG evades phagosome maturation, autophagy, and reduces MHC-II expression of antigen-presenting cells (APCs) affecting T-cell activation. To bypass these defects, an autophagy-inducing, TLR-2 activating C5 peptide from Mtb-derived CFP-10 protein was overexpressed in BCG in combination with Ag85B. Recombinant BCG85C5 induced a robust MHC-II-dependent antigen presentation to CD4 T cells in vitro, and elicited stronger TH1 cytokines (IL-12, IL-1β, and TNFα) from APCs of C57Bl/6 mice increasing phosphorylation of p38MAPK and ERK. BCG85C5 also enhanced MHC-II surface expression of MΦs by inhibiting MARCH1 ubiquitin ligase that degrades MHC-II. BCG85C5 infected APCs from MyD88 or TLR-2 knockout mice showed decreased antigen presentation. Furthermore, BCG85C5 induced LC3-dependent autophagy in macrophages increasing antigen presentation. Consistent with in vitro effects, BCG85C5 markedly expanded both effector and central memory T cells in C57Bl/6 mice protecting them against both primary aerosol infection with Mtb and reinfection, but was less effective among TLR-2 knockout mice. Thus, BCG85C5 induces stronger and longer lasting immunity, and is better than BCG against tuberculosis of mice.

AB - Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis due to M. tuberculosis (Mtb), which kills millions of people each year. BCG variably protects children, but not adults against tuberculosis. BCG evades phagosome maturation, autophagy, and reduces MHC-II expression of antigen-presenting cells (APCs) affecting T-cell activation. To bypass these defects, an autophagy-inducing, TLR-2 activating C5 peptide from Mtb-derived CFP-10 protein was overexpressed in BCG in combination with Ag85B. Recombinant BCG85C5 induced a robust MHC-II-dependent antigen presentation to CD4 T cells in vitro, and elicited stronger TH1 cytokines (IL-12, IL-1β, and TNFα) from APCs of C57Bl/6 mice increasing phosphorylation of p38MAPK and ERK. BCG85C5 also enhanced MHC-II surface expression of MΦs by inhibiting MARCH1 ubiquitin ligase that degrades MHC-II. BCG85C5 infected APCs from MyD88 or TLR-2 knockout mice showed decreased antigen presentation. Furthermore, BCG85C5 induced LC3-dependent autophagy in macrophages increasing antigen presentation. Consistent with in vitro effects, BCG85C5 markedly expanded both effector and central memory T cells in C57Bl/6 mice protecting them against both primary aerosol infection with Mtb and reinfection, but was less effective among TLR-2 knockout mice. Thus, BCG85C5 induces stronger and longer lasting immunity, and is better than BCG against tuberculosis of mice.

UR - http://www.scopus.com/inward/record.url?scp=85070208963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070208963&partnerID=8YFLogxK

U2 - 10.1038/s41541-019-0122-8

DO - 10.1038/s41541-019-0122-8

M3 - Article

C2 - 31396406

AN - SCOPUS:85070208963

VL - 4

JO - npj Vaccines

JF - npj Vaccines

SN - 2059-0105

IS - 1

M1 - 34

ER -